Accelerate Diagnostics up 13% on FDA emergency use nod for COVID-19 test

Accelerate Diagnostics (NASDAQ:AXDX) announces FDA emergency use authorization of privately held BioCheck’s SARS-CoV-2 IgM and IgG Combo Test and its fully automated MS-Fast instrument.

Accelerate will commercialize the chemiluminescence test and analyzer in the U.S. per the companies’ agreement inked in April.

https://seekingalpha.com/news/3606870-accelerate-diagnostics-up-13-on-fda-emergency-use-nod-for-covidminus-19-test